The product, which was developed jointly with Celltrion, is a biosimilar of Roche’s breast cancer blockbuster Herceptin (trastuzumab).

CT-P6 is the second monoclonal antibody biosimilar that Nippon Kayaku has brought to Japan. The company received MHLW approval for its biosimilar Infliximab BS in July 2014 [1]. Both biosimilars were developed as part of Nippon Kayaku’s November 2010 cooperation agreement with Celltrion for development and marketing of several biosimilars.

Nippon Kayaku now has three biosimilars filed or approved. The company also started marketing Filgrastim BS in 2013. The filgrastim biosimilar was produced in collaboration with development partner Teva Pharmaceutical Industries [2].

Related article
EC approves first monoclonal antibody biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilar infliximab receives approval in Japan and Turkey [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 14]. Available from: www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-receives-approval-in-Japan-and-Turkey
2. GaBI Online - Generics and Biosimilars Initiative. Japan approves second biosimilar G-CSF [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 14]. Available from: www.gabionline.net/Biosimilars/News/Japan-approves-second-biosimilar-G-CSF

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.